A number of studies suggest a role for PTHrP and the classical PTH/PTHrP receptor (type I) in one of the first differentiation processes in mouse embryogenesis, i.e. the formation of parietal endoderm (PE). We previously reported that although in type I receptor (−/−) embryos PE formation seemed normal, the embryos were smaller from at least day 9.5 p.c. and 60% had died before day 12.5 p.c. Here we show that the observed growth defect commences even earlier, at day 8.5 p.c. Using two novel antibodies, we show that the expression of the type I receptor protein at this stage is confined to extraembryonic endoderm only. In addition, we show that large amounts of PTHrP protein are present in the adjacent trophoblast giant cells, suggesting a paracrine interaction of PTHrP and the type I PTH/PTHrP receptor in PE formation. The involvement in PE differentiation of other recently described receptors for PTHrP would explain a possible redundancy for the type I receptor in PE formation. However, deletion of the type I PTH/PTHrP receptor in ES cells by homologous recombination completely prevents PTHrP-induced PE differentiation. Based upon these observations, we propose that PTHrP and the type I PTH/PTHrP receptor, although not required for the initial formation of PE, are required for its proper differentiation and/or functioning.
Introduction
PTHrP was initially identified in tumors associated with humoral hypercalcemia of malignancy, and was since then shown to be important in a wide range of growth and differentiation processes (reviewed in Mallette, 1991; Orloff et al., 1994) . The N-terminus of PTHrP, PTHrP(1-34), contains the PTH-like portion of this molecule, and is comparable with PTH(1-34) in binding and activation of the classical PTH/PTHrP receptor (type I) (Abou-Samra et al., 1992) . While PTH and the type I receptor are known to serve an important role in regulation of calcium homeostasis in the adult organism (reviewed in Mallette, 1991) , we and others have suggested a role for PTHrP and the type I receptor in the formation of parietal endoderm (PE) in the early mouse embryo (Chan et al., 1990; van de Stolpe et al., 1993; Karperien et al., 1994 Karperien et al., , 1996 Behrendtsen et al., 1995) . However, mice in which the type I receptor gene was ablated did not show obvious abnormalities in PE formation . Histologial analysis of the PE of these mice suggested that this cell layer developed normally, although the mice were smaller than normal from at least Mechanisms of Development 81 (1999) [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] 0925-4773/99/$ -see front matter © 1999 Elsevier Science Ireland Ltd. All rights reserved. PII: S0925-4773(98)00240-8 day 9.5 p.c., while, depending on the genetic background, 60% had died at day 12.5 p.c.
It was thought for a long time that the type I PTH/PTHrP receptor was involved in almost all of the actions of the Nterminal PTH and PTHrP fragments. However, with the recent discovery of additional receptors for N-terminal, midregion and C-terminal fragments of PTH and/or PTHrP, this concept is no longer tenable (Fenton et al., 1991; Fukayama et al., 1995; Orloff et al., 1995; Usdin et al., 1995; Kovacs et al., 1996; Yamamoto et al., 1997) . The presence of these other receptors for PTH and/or PTHrP might explain the residual PE formation in type I receptor (−/−) embryos.
Here, we present data which indicate that PTHrP exerts its actions in PE formation exclusively through the type I receptor, and furthermore suggest that PTHrP and the type I receptor are required for proper differentiation and/or functioning of PE.
Results

Type I PTH/PTHrP receptor (−/−) embryos are growth retarded at day 8.5 p.c
We previously reported that type I receptor (−/−) embryos are smaller from at least day 9.5 p.c. . To examine the growth retardation during this stage of development in more detail, we directly measured the length of isolated embryos, and also included 8.5 p.c embryos in the analysis. For 9.5 p.c. embryos the crownrump length was measured (Brown, 1990) . Since for day 8.5 p.c. embryos, which have not yet turned this analysis cannot be performed, the length of such embryos was measured differently, i.e. as the distance between a line touching the tips of the U-shaped embryo and a line touching the bottom of the U. Importantly, there was no difference in the curvature between wt, +/− or −/− embryos. Only embryos which had not turned yet were analyzed. No differences were observed between the length of wildtype and heterozygous embryos, while 90% of the type I receptor (−/−) embryos were shorter than wildtype/heterozygous embryos at both day 8.5 as well as day 9.5 p.c. (Table 1 ). The shorter length of (−/−) embryos was already significant at day 8.5 p.c., and became even more pronounced at day 9.5 p.c. Type I receptor (−/−) embryos showed no significant differences in the number of somites compared to wildtype/heterozygous embryos (data not shown). Thus type I receptor (−/−) embryos are already growth retarded at day 8.5 p.c., suggesting defective formation of the extraembryonic endoderm, the only site of receptor mRNA expression at this stage (Karperien et al., 1994) .
PTHrP-induced PE differentiation of ES cells is dependent on the type I PTH/PTHrP receptor
To investigate the possible involvement of other receptors for PTH and/or PTHrP than the type I PTH/PTHrP receptor in PE differentiation, we determined the effect of different PTH and PTHrP fragments on PE differentiation of wild type ES cells and of ES cells with a homozygous deletion of the type I PTH/PTHrP receptor gene established from type I PTH/PTHrP receptor knockout mice (see Section 4) . In this study, we performed experiments with the wildtype ES cell line 9(+/ + ) and the knock out ES cell lines 1(−/−) and 5(−/−). Since no experimental differences were observed between ES 1 (−/−) and 5(−/−), only results with ES 5(−/−) are shown. Differentiation to PE was determined using the PE marker thrombomodulin (Imada et al., 1987; Weiler-Guettler et al., 1996) and by the changes in morphology (Strickland and Mahdavi, 1978; Strickland et al., 1980; van de Stolpe et al., 1993) . No expression of thrombomodulin could be detected in undifferentiated ES cells. However, addition of RA for 6 d induced low expression of thrombomodulin in ES(9+/+) cells (Fig. 1A) . Thrombomodulin was expressed at sites of high confluency by a few cells with a PE-like morphology (small and rounded cells with long filopodia) and not by the majority of the cells with a PrE-like morphology (flattened and epithelial-like cells) (see Fig. 4 and Fig. 5B ). Treatment with the N-terminal fragments, PTH(1-34) and PTHrP(1-34), or the full length versions of these molecules, PTH(1-84) and PTHrP(1-141), induced a PE-like morphology and a strong increase in thrombomodulin expression (Figs. 1A and 5B). Quantification by densitometric scanning of the autoradiogram in Fig. 1A revealed these increases to be 4- (Fig. 1B) , which was expressed at sites of high confluency by a few cells with a PE-like morphology. Subsequent treatment with the different PTH(rP) fragments during the last 3 days did not elevate thrombomodulin expression (Fig. 1B) nor did it increase the amount of cells with a PE-like morphology. Importantly, dbcAMP was perfectly able to induce thrombomodulin expression (Fig. 1B) and a PE-like morphology (Fig. 5B) , showing that the ES5(−/−) cells were not impaired in their capacity to form PE. Thus, the type I receptor is necessary for the PTHrPinduced PE differentiation. Furthermore, the observation that treatment with RA is sufficient to induce some PE differentiation in ES 5(−/−) cells suggests that this 'spontaneous' differentiation to PE is not caused by an autocrine mechanism involving PTHrP and the type I PTH/PTHrP receptor, as was previously suggested (van de Stolpe et al., 1993) . We therefore conclude that the type I PTH/ PTHrP receptor is essential for the PTHrP-induced PE differentiation of ES cells, and that other mechanisms can contribute to PE differentiation as well.
Characterization of anti-type I PTH/PTHrP receptor antibodies
Two novel antibodies A27 and P31, directed against, respectively, the extracellular N-terminus and the intracellular C-terminus of the receptor (see Section 4) were tested by Western blotting using cell extracts of COS or 293 cells transiently transfected with mouse type I receptor expression vector (cMR13). Both P31 as well as A27 recognized a band with the expected molecular weight of approximately 85 kDa in 293 cells ( Fig. 2A ) and COS cells (Fig. 2B ) transfected with cMR13 but not in mock transfected cells (Karpf et al., 1987; Shigeno et al., 1988) . A band of approximately 160-180 kDa could be detected also and might present a dimer of the receptor. However, other bands with a molecular weight of approximately 60 and 70 kDa were detected in COS cells as well. Since the type I receptor contains four putative N-linked glycosylation sites, the bands of 60 and 70 kDa could represent less glycosylated receptor protein. Inhibition of N-linked glycosylation with tunicamycin resulted in strong expression of the 60 kDa band, which thus likely represents the putative backbone of the type I receptor, and a band of approximately 120-140 kDa which could represent a dimer of unglycosylated type I receptors (Fig. 2B) . Dimerization or microaggragation has previously been demonstrated for the b2-adrenergic receptor and the gonadotropin releasing hormone receptor. and shown to be stabilized by agonist treatment (Hebert et al., 1996; Janovick and Conn, 1996) . The biological relevance of the putative type I receptor dimers and their existence under more physiological circumstances remains to be determined.
We could not detect any expression of type I PTH/PTHrP receptor protein in undifferentiated F9 EC cells, while low, but detectable, expression was found during RA-induced differentiation towards PrE (Fig. 3A) . Subsequent differentiation to PE, by addition of PTHrP or dbcAMP, was accompanied by a strong upregulation of receptor expression (Fig.  3A) . The molecular weight of the receptor in PrE and PElike cells was 85 kDa, suggesting that it was normally glycosylated during this differentiation process. Differentiation to PE was confirmed by Western blotting on thrombomodulin. As shown in Fig. 3B , thrombomodulin was not expressed, or at very low levels, in undifferentiated or RA-induced PrE-like cells, while subsequent differentiation to PE by treatment with PTHrP or dbcAMP strongly induced thrombomodulin expression. The identity of the cells expressing the type I receptor was determined by immunofluorescence. As expected from the Western blotting experiments, we could not find any expression in undifferentiated cells (Fig. 4) , while RA-induced differentiation to a PrE-like phenotype resulted in expression of the receptor at low levels. Treatment of PrE-like cells with PTHrP or dbcAMP strongly induced expression of the type I receptor in cells differentiated to a PE-like phenotype. Specificity of the antibodies was confirmed using Western blotting and immunofluorescence on ES 9(+/+) and ES 1(−/−) cells. (Fig. 5A) . The sharp band of approximately 80 kDa, which in ES 9(+/+) cells runs close to the receptor band of 85 kDa, can be detected in ES 5(−/−) cells as well, suggesting that it is recognized non-specifically. The phenotype of the cells expressing the type I receptor was determined using immunofluorescence. As shown in Fig. 5B , receptor expression was only observed in ES 9(+/+) cells with a PE-like morphology. Again, no receptor staining could be detected in ES 5(−/−) cells, before or after differentiation by RA and dbcAMP, confirming once more the specificity of the antibody.
The type I PTH/PTHrP receptor protein is expressed in parietal and visceral endoderm of early implantation embryos
To investigate whether the type I receptor protein is indeed expressed at sites involved in PE differentiation, we performed immunohistochemistry with both A27 and P31 antibodies. The earliest stages in which we observed expression were early postimplantation embryos of approximately day 5.5 p.c. The embryos were left in utero and embedded as such in paraffin, or were frozen in tissue freezing medium, sectioned and stained for the type I PTH/ PTHrP receptor with antibodies P31 and A27, as described in Section 4. As shown in Fig. 6A , the receptor was detected at high levels in tissue of both embryonal and maternal origin. This staining was specific since both antibodies showed identical staining patterns, while no staining was observed when the first antibody was omitted (not shown). Maternal type I receptor was expressed in the outer zone of the decidua and in the inner circular myometrial smooth muscle layers. This expression pattern is consistent with a proposed role for PTHrP in relaxation of uterine smooth muscles and inhibition of uterus contractility before partus (Thiede et al., 1991; Daifotis et al., 1992; Paspaliaris et al., 1992; Williams et al., 1994) . Embryonic type I PTH/PTHrP receptor was detected only in the extraembryonic cell layers, being PE and VE (Fig. 6B) . A comparable expres- sion pattern was observed for the type I PTH/PTHrP receptor in the 6.5 day p.c. embryo (Fig. 6D) , while only background staining was detected in the control (staining procedure when first antibody was omitted, Fig. 6C ). Interestingly, high levels of receptor expression were found in the marginal zone, a region where PE and VE are in close contact, and from which PE cells are recruited (Hogan and Newman, 1984) . The visceral endoderm cells near the marginal zone have been demonstrated to possess the capacity to differentiate to PE cells until day 7.5 p.c. (Hogan and Tilly, 1981; Cockroft and Gardner, 1987) . It was at this stage that we observed a decrease in expression of the type I PTH/PTHrP receptor in VE, compared to earlier stages, while expression in PE was still high (Fig. 6F) . No expression could be detected at other sites, although some staining was detected in embryonic tissue between the ectoderm and mesoderm, which was however non-specific since a similar staining was observed in the control (Fig. 6E) . Type I receptor (−/−) embryos of day 8.5 and 9.5 p.c. are smaller than normal (see above). Importantly, while the only site of expression of the type I PTH/PTHrP receptor protein until 7.5 p.c. was in PE and VE, the only site of expression at day 9.5 p.c. was in PE, which can be recognized as a single cell layer between the trophoblasts giant cells and the visceral yolk sac (Fig. 6G) . No staining was detected in the marginal zone, the VE or in the embryo proper (not shown). This suggests that the phenotype of type I receptor (−/−) embryos, at least the smaller size observed at day 8.5 and 9.5 p.c., is a consequence of a lack of the type I receptor in (developing) PE.
To measure PTHrP protein expression in the 9.5 p.c. embryo we used affinity-purified rabbit anti-PTHrP (34-54) IgG. PTHrP protein was strongly expressed in the trophoblast giant cells (Fig. 6H) . while no expression could be detected in embryonic tissues (not shown) nor in VE or PK. Thus, PTHrP and the type I receptor show a complementary expression pattern during early embryonic development.
Discussion
ES cells are an established model system for early embryonic events. They are considered to represent undifferentiated inner cell mass cells, and can be differentiated in vitro to form derivatives of all three germ layers, including extraembryonic endoderm. PTHrP is an established inducer of PE differentiation in vitro (Chan et al., 1990; van de Stolpe et al., 1993) . We show here that the PTHrP fragments (67-86), (67-94) and (107-139), for which receptors other than the type I PTH/PTHrP receptor have been described (Fenton et al., 1991; Fukayama et al., 1995; Orloff et al., 1995; Usdin et al., 1995; Kovacs et al., 1996; Yamamoto et al., 1997) , do not induce differentiation of ES cells to PE, in contrast to PTHrP fragments containing the N-terminus. Furthermore, the induction of PE by PTHrP(1-34) or PTHrP(1-141) was prevented by homozygous deletion of the type I PTH/PTHrP receptor. Thus, we conclude that PTHrP-induced PE differentiation, at least of ES cells, is mediated exclusively by the type I PTH/PTHrP receptor.
The expression pattern of the type I PTH/PTHrP receptor protein observed in vivo was identical to that of its mRNA, as observed by in situ hybridization (Karperien et al., 1994) . Expression of type I PTH/PTHrP receptor protein was found in PE and VE of day 5.5 and 6.5 p.c. embryos. Interestingly, high amounts of type I PTH/PTHrP receptor protein were detected in the marginal zone, the region were VE and PE are in close contact and from which PE cells are recruited (Hogan and Newman, 1984) . Visceral endoderm cells near the marginal zone have been demonstrated to possess the capacity to transdifferentiate into PE cells until day 7.5 p.c. (Hogan and Tilly, 1981; Cockroft and Gardner, 1987) . This correlated with the expression of type I PTH/PTHrP receptor protein found in this study, since expression in VE and the marginal zone decreased at day 7.5 p.c., while it could no longer be detected in these cell layers at day 9.5 p.c. The only site of type I PTH/PTHrP receptor expression at this stage was PE. Type I PTH/PTHrP receptor protein expression was complementary to expression of PTHrP protein in the trophoblast giant cells. The expression patterns of PTHrP and the type I PTH/PTHrP receptor thus strongly confirm the notion that this signaling system is involved in PE formation in a paracrine fashion.
The role of PTHrP and the type I PTH/PTHrP receptor in PE differentiation in vivo
If PTHrP and the type I PTH/PTHrP receptor play a critical role in PE formation, mice with a homozygous deletion for either gene would be expected to die early in gestation because of defects in the parietal yolk sac. However, PTHrP(−/−) mice have developed a seemingly normal PE early in gestation, but die at birth (Karaplis et al., 1994) . A more severe phenotype is seen for type I PTH/PTHrP receptor (−/−) mice . These mice are smaller than normal at day 8.5 p c. (this study), while, depending on the genetic background, 60% has died at day 12.5 p.c. Again, no obvious abnormalities are observed in the PE. Although detailed analysis of the PE of these mice is still lacking, the phenotypes suggest that PTHrP and the type I PTH/PTHrP receptor are not essential for formation of PE. Lack of fetal PTHrP in early gestation of PTHrP (−/−) embryos, could likely be compensated for by maternally derived PTHrP. Indeed, high levels of PTHrP mRNA and protein were observed in the maternal tissue surrounding the embryo  this study), which might result in transfer of maternal PTHrP to the embryo, a phenomenon described previously for knock outs of other growth factors such as TGFb 1 (Shull et al., 1992) . We hypothesized that the lack of a clear phenotype in early gestation of type I PTH/PTHrP receptor (−/−) embryos could be due to compensation by other receptors for PTH or PTHrP. However, our present data clearly show that none of the PTH(rP) fragments could enhance PE differentiation in type I PTH/PTHrP receptor (−/−) ES cells, indicating that at least in vitro this was not the case. Our data indicate that the type I PTH/PTHrP receptor protein was expressed exclusively in the VE and PE, and not at other sites, until at least day 9.5 p.c. Although it can not be excluded that the type I receptor has a function in extraembryonic VE other than stimulating the formation of PE, the smaller size of the type I PTH/PTH-TrP receptor (−/−) embryos at day 8.5 p.c. strongly suggests that PTHrP and the type I PTH/PTHrP receptor are required for proper PE differentiation and/or functioning. In relation to this, the phenotype of thrombomodulin (−/−) embryos is striking, since at day 8.5 p.c. these mice are smaller than normal, while the embryo's failed to survive beyond day 9.5 p.c. Since no obvious pathological abnormalities were observed, and the only site of expression before day 9.5 p.c. was the parietal yolk sac, it was suggested that the failure of thrombomodulin (−/−) embryos to survive was consequence of dysfunctional maternal-embryonic interaction (Healy et al., 1995) . We observed that exogenous PTHrP can strongly increase thrombomodulin expression in RA-treated ES cells Whether thrombomodulin expression levels are affected in type I PTH/PTHrP receptor (−/−) embryos remains to be determined.
Since type I receptor (−/−) embryos show formation of PE, the type I receptor is apparently not essential for (initial) PE formation. This is supported by our in vitro data using the type I PTH/PTHrP (−/−) ES cells. Although these cells do not respond to PTHrP they can still differentiate to PE, indicating that other signals are involved in PE differentiation as well. Recently, Behrendtsen et al. (1995) showed that differentiation and outgrowth of PE from isolated ICM is a cooperative interaction between extracellular matrix, integrins and PTHrP. This suggests that signals induced by extracellular matrix components might compensate for the lack of PTHrP-induced signals in type I PTH/PTHrP receptor (−/ −) embryos.
In conclusion, PTHrP-induced stimulation of PE differentiation is solely mediated by the type I PTH/PTHrP receptor. The expression patterns of the type I PTH/PTHrP receptor protein and the PTHrP protein are strongly consistent with the role for this signaling system as stimulators of PE differentiation in vivo. The observation that VE and PE are the only sites of type I PTH/PTHrP receptor expression until at least day 9.5 p.c. suggests the phenotype of type I PTH/PTHrP receptor (−/−) embryos at this stage to be explained by improper differentiation and/or functioning of PE. Detailed analysis of PE in these mice will therefore be the subject of further study. Our results are consistent with a model proposed by others, in which PrE cells, of VE cells with PrE-like characteristics, are induced to differentiate into PE and to migrate from the marginal zone over the trophectoderm by a cooperation of signals induced by PTHrP and other factors, like extracellular matrix components. We propose that PTHrP, although not required for initial PE differentiation, is essential for proper differentiation and/or function of PE.
Experimental procedures
Materials
dbcAMP was purchased from Aldrich (Zwijndrecht, the Netherlands); ECL from Amersham (Hertogenbosch, The Netherlands); All-trans RA and tunicamycin were from Sigma rat PTH(1-34) was purchased from Peninsula Laboratories Europe (St. Helens, UK); PTHrP(1-34) from Bachem (Bubendorf, Switzerland); PTHrP(67-86), PTHrP(67-94) hPTHrP(107-139) and hPTHrP(1-141) were a gift from Jane Moseley (University of Melbourne, Australia). Recombinant hPTH(1-84) was obtained as described previously (Inomata et al., 1995) , using a bacterial expression vector for full length hPTH, kindly provided by Dr. H. Jüppner (Massachusetts General Hospital and Harvard Medical School, Boston, MA) . Affinity-purified polyclonal rabbit anti-human PTHrP(34-53) IgG were purchased from Oncogene Science (Mineola, NY). Monoclonal antibodies against thrombomodulin were a gift from Dr. S.J. Kennel (Oak Ridge National Laboratory, Oak Ridge, TN).
Embryos
Embryos homozygous for the PTH/PTHrP receptor gene were obtained by mating of heterozygous mice of mixed genetic background C57BL/6-129/SvJ-CBA. For the immunohistochemical study on PTHrP and type I PTH/PTHrP receptor expression, F1 embryos were obtained from C57BL/6 females mated to CBA males. The embryos were kept on a 14:10 h light-dark rhythm. Gestation was assumed to have begun in the middle of the dark period.
Genotyping of the embryos was performed by PCR. Length of embryos was measured before fixation. after removing the extraembryonic membranes and leaving the embryo intact.
Immunohistochemistry
Embryos were fixed in 4% buffered paraformaldehyde and embedded in paraffin, except for Fig. 6C ,D, where sections used were obtained from embryos which were quickfrozen in tissue freezing medium (Electron Microscopy Center, Washington). Deparafinized 6 mm sections were treated with 1% H 2 O 2 in 40% methanol for 20 min to block endogenous peroxidase activity, and subsequently pretreated with 0.03% pepsin (Sigma) in diluted HCl (pH 2.0) for 8 min at 37°C. Blocking of non-specific binding and all subsequent antibody incubations were performed in 0.5% Boehringer Milk Powder (BMP) dissolved in TNT (100 mM Tris, 150 mM NaCl, 0.05% Tween-20, and 0.04% Triton X-100). Incubation of first antibody was overnight at 4°C. After washing with TNT, sections were incubated with biotinylated secondary antibody (Amersham) for 45 min at 37°C, washed with TNT and incubated with horseradish peroxidase conjugated streptavidin (Amersham) for 30 min at 37°C. Signals were amplified by peroxidase induced deposition of biotinylated tyramides using the signal amplification kit of DuPont. After washing, sections were incubated with horseradish peroxidase conjugated streptavidin for 30 min at 37°C, washed and signals were developed using 3-amino-9-ethylcarbazole (AEC, Sigma). Sections were counterstained using hematoxy in and mounted in Kaisers glycerin.
Establishment of ES cell lines with a homozygous deletion of the type I PTH/PTHrP receptor gene
ES cell lines were established as previously described (Robertson, 1987) . In short, first to introduce a b-galactosidase transgene as marker, C57BL/6 mice heterozygous for the type I PTH/PTHrP receptor knock-out were mated with C57BL/6 mice carrying a b-galactosidase transgene which was engineered to be expressed ubiquitously (Zambrowicz et al., 1997) . By further mating, mice heterozygous for the type I PTH/PTHrP receptor knock-our and homozygous for the b-galactosidase transgene were made. They were then mated with mice heterozygous for the PTH/PTHrP receptor knock-out to produce blastocysts. Collected blastocysts were placed onto fibroblasts feeder layers and cultured. When blastocysts hatched and ICMs proliferated, ICMs were isolated from underlying trophoblasts and cultured onto new feeder layers. After about a week, ES cells were identified, isolated and cultured further. From 34 collected blastocysts, 17 new ES cell lines were successfully established. Among them, 13 lines were genotyped by Southern blot. All of them were heterozygous for the b-galactosidase transgene, as expected. Four of them were homozygous for the type I PTH/PTHrP receptor knock-out, four of them heterozygous, and five of them wild-type. In this study, experiments were performed with the wild-type ES cell line 9(+/+), and the knock out ES cell lines 1(−/−) and 5(−/−).
Cell culture and transfections
F9 EC cells (ATCC) and ES cells were cultured as described elsewhere (van de Stolpe et al., 1993) . Transient transfections were performed using the calcium phosphate precipitation method. One day prior to transfection, the COS-7 or 293 cells were plated at a density of 2 × 10 c/ cm 2 in six-well tissue culture clusters. The following day cells were transfected with a mouse type I PTH/PTHrP receptor expression vector (cMR13, Karperien et al., 1996) or an empty expression vector.
Generation and affinity-purification of anti-type I PTH/ PTHrP receptor antibodies
Plasmids encoding for GST-fusion protein with either a part of the extracellular domain or the C-terminal intracellular domain of the mouse type I PTH/PTHrP receptor (cMR13), were produced by cloning of, respectively, an AvaI restriction fragment coding for amino acid 90-179 and a PvuII restriction fragment coding for amino acid 531-589, into pGEX-3X (Promega). Expression and purification of GST fusion proteins were done as previously described (Smith, 1993) .
Antisera were obtained by primary immunization of New Zealand White rabbits via subcutaneous injection of 100 mg GST fusion protein coupled to glutathione-agarose beads in Freund's complete adjuvant, followed by booster immunizations with 100 mg GST fusion protein in Freund's incomplete adjuvant for every 4 weeks. The animals were bled 10 days after each boost. The antibodies A27 and P31, directed against, respectively, the extracellular and intracellular part of the type I PTH/PTHrP receptor, were affinity-purified as previously described (Koff et al., 1992) .
Western blotting
Cells were washed twice with ice-cold PBS, scraped in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 20 mg/ml leupeptin, 20 mg/ml aprotinin and 3 mM phenylmethylsulfonylfluoride), and protein concentrations of the lysates were determined. Preparation of samples for Western blotting on thrombomodulin was done by adding of appropriate amounts of non-reducing sample buffer (Laemmli sample buffer without p-mercaptoethanol), and heating for 5 min at 95°C. Preparation of samples for Western blotting on the type I PTH/PTHrP receptor was done by adding of appropriate amounts of urea saturated non-reducing sample buffer, and shearing of the samples through a needle. Equal amounts of proteins were loaded on a 10% SDS-polyacrylamide gel blotted to Immobilon-P PVDF membrane, incubated with A27, P31 or anti-thrombomodulin monoclonal antibody 273-34A (Kennel et al., 1987) , and subsequently incubated with peroxidase-labeled secondary antibody, followed by ECL. The fold increase in thrombomodulin levels was quantified by computerized densitometry using NIH Image.
Immunofluorescence
Cells were washed twice with PBS, fixed with 2% paraformaldehyde, and incubated with 20 mM NH 4 Cl for 30 min. For detection of type I PTH/PTHrP receptor with antibody A27 or P31, cells were incubated with, respectively, PBS/ 0.2% BSA for 1 h or treated with 0.1% Triton for 5 min prior to incubation with PBS/0.2% BSA for 1 h. Subsequent antibody incubations were done in PBS/0.2% BSA as well. Detection of thrombomodulin was performed as previously described (Verheijen et al., 1999) . Incubations with first antibodies were for 1 h at RT, the cells were rinsed extensively in PBS, and incubated with CY3-conjugated secondary antibodies (Jackson Immunoresearch, West Groove, PA) for 1 h at RT, again extensively rinsed, and mounted in Moviol.
